Antigen Information

General Information of This Antigen (ID: TAR0SYQPS)
Antigen Name
Programmed cell death 1 ligand 1 (PD-L1)
Gene Name
PD-L1
Gene ID
29126
Synonym1
B7H1, PDCD1L1, PDCD1LG1, PDL1
Sequence1
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV

    Click to Show/Hide
Family1
BTN/MOG family
Function1
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function.

    Click to Show/Hide
Uniprot Entry
PD1L1_HUMAN
HGNC ID
HGNC:17635
KEGG ID
hsa:29126
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Anti-mouse PD-L1 (B7-H1)
 Antibody Info 
ADC Name Payload Target Linker ADC Info
WO2023232144A1ADC38 [1]
WO2025015586A1, ADC34, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC39 [1]
WO2025015586A1, ADC35, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC40 [1]
WO2025015586A1, ADC34, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
WO2023232144A1ADC41 [1]
WO2025015586A1, ADC35, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
Anti-PD-L1 antibody
 Antibody Info 
ADC Name Payload Target Linker ADC Info
SKB103
KL610348
DNA topoisomerase 1 (TOP1)
Kthiol (pyrimidine-thiol) AAA linker
 ADC Info 
PF-08046037 [2]
Imidazoquinoline-based TLR7 agonist
Toll-like receptor 7 (TLR7)
Mannosidase-cleavable maleimidopropionyl-mannose linker
 ADC Info 
Anti-PD-L1 SGN-PDL1V mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Fetrastobart vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Atezolizumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
PD-L1 ADC 3 [3]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Ala-PABC
 ADC Info 
Atezolizumab ADC [3]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
PDL1-Dox ADC [4]
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Undisclosed
 ADC Info 
40460724 ADC A9 [5]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
40460724 ADC A10 [5]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Pemetrexed-GABA-mAb conjugate [6]
Pemetrexed
Undisclosed
Gamma-Aminobutyric acid (GABA)
 ADC Info 
Pemetrexed-PEG-mAb conjugate [6]
Pemetrexed
Undisclosed
NH2-PEG4-COOH
 ADC Info 
39914224 Ate-36 [7]
Monomethyl auristatin E
Microtubule (MT)
Phenoxy silyl linker 36
 ADC Info 
39914224 Ate-37 [7]
Monomethyl auristatin E
Microtubule (MT)
Phenoxy silyl linker 37
 ADC Info 
39914224 Ate-38 [7]
Monomethyl auristatin E
Microtubule (MT)
Phenoxy silyl linker 38
 ADC Info 
39914224 Ate-39 [7]
Monomethyl auristatin E
Microtubule (MT)
Phenoxy silyl linker 39
 ADC Info 
Atezolizumab-Immunoconjugate A [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate B [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate C [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate D [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate E [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate F [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate G [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate H [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate I [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate J [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate L [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate M [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate N [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate O [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate P [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate Q [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate R [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate S [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate T [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate U [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate V [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
Atezolizumab-Immunoconjugate K1 [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
US20220226491A1 Immunoconjugate R1 [8]
undisclosed
Undisclosed
Undisclosed
 ADC Info 
TW202436324A ADC-1.1 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-1.2 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-1.3 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-1.4 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-1.5 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-1.6 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
Mal-PEG2-Val-Cit-PAB
 ADC Info 
TW202436324A ADC-2 [9]
TW202436324A+ADC-2+payload
Undisclosed
TW202436324A+ADC-2+Linker
 ADC Info 
TW202436324A ADC-3.1 [9]
TW202436324A+ADC-3.1payload
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
TW202436324A ADC-3.2 [9]
TW202436324A+ADC-3.1payload
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
TW202436324A ADC-3.3 [9]
TW202436324A+ADC-3.1payload
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
TW202436324A ADC-3.4 [9]
TW202436324A+ADC-3.1payload
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
TW202436324A ADC-4 [9]
TW202436324A+ADC-4+payload
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
TW202436324A ADC-5 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
TW202436324A+ADC-5+Linker
 ADC Info 
TW202436324A ADC-6 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
TW202436324A+ADC-6+Linker
 ADC Info 
TW202436324A ADC-7 [9]
TW202436324A+ADC-1.1+payload
Undisclosed
TW202436324A+ADC-7+Linker
 ADC Info 
CN115364238B Compound 4 [10]
CN115364238B+Compound 4+payload
Undisclosed
CN115364238B+Compound 4+Linker
 ADC Info 
WO2023232144A1ADC44 [1]
WO2025015586A1, ADC35, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
ADC Name Payload Target Linker ADC Info
PD-L1 ADC 1 [3]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Ala-PABC
 ADC Info 
PD-L1 ADC 2 [3]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
ADC HE-S2 [11]
Bifunctional immunomodulator D18
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Disulfide linker 8
 ADC Info 
AU2020291014A1 IC-9 [12]
AU2020291014A1-Payload-70
Undisclosed
Aminobenzazepine-linker Formula II-15
 ADC Info 
AU2020291014A1 IC-15 [12]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 23p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 29p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 30p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 31p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 32p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 34p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 36p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 37p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 38p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 39p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 40p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 42p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 43p-Avelu 1 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 23p-Avelu 2 [13]
Mdo-cpt
DNA topoisomerase I (TOP1)
23i-5657 Linker
 ADC Info 
WO2023232144A1ADC26 [1]
WO2025015586A1, ADC22, Payload
DNA topoisomerase I (TOP1)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC27 [1]
WO2025015586A1, ADC23, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC28 [1]
WO2025015586A1, ADC24, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC29 [1]
WO2025015586A1, ADC25, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Mc-Val-Cit-PABC
 ADC Info 
WO2023232144A1ADC31 [1]
WO2025015586A1, ADC25, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
WO2023232144A1ADC33 [1]
WO2025015586A1, ADC22, Payload
DNA topoisomerase I (TOP1)
SMCC
 ADC Info 
WO2023232144A1ADC42 [1]
WO2025015586A1, ADC34, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
WO2023232144A1ADC43 [1]
WO2025015586A1, ADC35, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
SMCC
 ADC Info 
WO2024105206A1 1p-Avelu [13]
CHH0170, 1i-5657, Payload
Undisclosed
32p-Avelu Linker
 ADC Info 
Bavdegalimab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
JP7560255B2 ControlADC54 [14]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
TWI857167B IC-4 [15]
TWI857167B-IC-2-PAYLOAD
Undisclosed
TWI857167B-IC-1-LINKER
 ADC Info 
TWI857167B IC-5 [15]
TWI857167B-IC-3-PAYLOAD
Undisclosed
Aminobenzazepine-linker Formula II-3
 ADC Info 
bsCTRL×HER2
 Antibody Info 
ADC Name Payload Target Linker ADC Info
bsCTRL×HER2-DXd [16]
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
bsSORT1×CTRL
 Antibody Info 
ADC Name Payload Target Linker ADC Info
bsSORT1×CTRL-DXd [16]
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
bsSORT1×HER2
 Antibody Info 
ADC Name Payload Target Linker ADC Info
bsSORT1×HER2-DXd [16]
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
HLX43
YL0010014
DNA topoisomerase 1 (TOP1)
VK*G-NHCH2-O linker
 ADC Info 
PDL1.24-GIF
 Antibody Info 
ADC Name Payload Target Linker ADC Info
TWI857167B IC-8 [15]
TWI857167B-IC-2-PAYLOAD
Undisclosed
TWI857167B-IC-1-LINKER
 ADC Info 
PDL1.85-GIF
 Antibody Info 
ADC Name Payload Target Linker ADC Info
TWI857167B IC-9 [15]
TWI857167B-IC-2-PAYLOAD
Undisclosed
TWI857167B-IC-1-LINKER
 ADC Info 
TPP-Avelumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
WO2024105206A1 29p-Avelu 2 [13]
Mdo-cpt
DNA topoisomerase I (TOP1)
29p-Avelu Linker
 ADC Info 
WO2024105206A1 30p-Avelu 2 [13]
22i-5657 Payload
Undisclosed
22i-5657 Linker
 ADC Info 
WO2024105206A1 31p-Avelu 2 [13]
41i-5657 Payload
Undisclosed
31p-Avelu Linker
 ADC Info 
WO2024105206A1 32p-Avelu 2 [13]
Mdo-cpt
DNA topoisomerase I (TOP1)
32p-Avelu Linker
 ADC Info 
WO2024105206A1 34p-Avelu 2 [13]
Monomethyl auristatin E
Microtubule (MT)
22i-5657 Linker
 ADC Info 
WO2024105206A1 36p-Avelu 2 [13]
Camptothecin
DNA topoisomerase 1 (TOP1)
36p-Avelu Linker
 ADC Info 
WO2024105206A1 37p-Avelu 2 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 38p-Avelu 2 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 39p-Avelu 2 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 40p-Avelu 2 [13]
Camptothecin
DNA topoisomerase 1 (TOP1)
40i-5657 Linker
 ADC Info 
WO2024105206A1 42p-Avelu 2 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
WO2024105206A1 43p-Avelu 2 [13]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
YB1-ADC-PDL1 [17]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
OX-001L ADC [18]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
OX-003 [19]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
BDB-101 [20]
TLR7/8 agonist
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Undisclosed
 ADC Info 
PD-L1 ISA [21]
TLR7/8 agonist
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Undisclosed
 ADC Info 
Anti-PDL1-PBA-Cur [22]
PBA-Cur
Undisclosed
Undisclosed
 ADC Info 
aPDL1-NPLG-SN38 [23]
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
NPLG
 ADC Info 
CN114786729A ADC-I [24]
CDN-B
Undisclosed
CN114786729A-ADC-I-Linker
 ADC Info 
CN114786729A ADC-II [24]
CDN-A
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
CN114786729A ADC-III [24]
CDN-B
Undisclosed
Undisclosed
 ADC Info 
CN114786729A ADC-IV [24]
CDN-B
Undisclosed
Undisclosed
 ADC Info 
CN114786729A ADC-V [24]
CDN-A
Undisclosed
Undisclosed
 ADC Info 
CN114786729A ADC-VI [24]
CDN-A
Undisclosed
Undisclosed
 ADC Info 
PF-08046054
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
References
Ref 1 Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
Ref 2 PF-08046037, a PD-L1 targeted TLR7 agonist ISAC, drives innate immune activation and anti-tumor efficacy in preclinical in vitro and in vivo models
Ref 3 Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov;116:105366.
Ref 4 PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232.
Ref 5 Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer
Ref 6 Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates
Ref 7 Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates
Ref 8 Immunoconjugates targeting PD-L1
Ref 9 A linker, antibody-drug conjugates comprising the linker, and preparation methods and uses
Ref 10 An atezolizumab-MMAD conjugate and its preparation method and uses
Ref 11 Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021 Nov 11;64(21):15716-15726. doi: 10.1021/acs.jmedchem.1c00961. Epub 2021 Nov 3.
Ref 12 Aminobenzazepine compounds, immunoconjugates, and uses thereof
Ref 13 Antibody-drug conjugates cleavable in a tumor microenvironment
Ref 14 Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 15 Thienobenzodiazepine immunoconjugates and uses thereof
Ref 16 Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor
Ref 17 YB1 pharmaceutical company product pipeline
Ref 18 Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development; 2018.
Ref 19 Oxford BioTherapeutics designates second bispecific antibody program leveraging WuXi Biologics's WuXiBody platform; 2021.
Ref 20 Seven and eight biopharmaceutical company produce pipeline
Ref 21 PD-L1-targeted ISAC combines myeloid cell activation, immune checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models; 2021
Ref 22 Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer
Ref 23 Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy
Ref 24 Antibody-STING agonist conjugates and their use in immunotherapy